A
Alphabet Inc.
+ HältSPRO
+0.00%
3-Monats-Rendite
$1.020
-0.048 (-4.67%)Zum Schluss
Loading chart…
- Hoch
- 1.070
- Eröffnung
- 1.070
- Volumengewichteter Durchschnittskurs
- 1.02
- Volumen
- 712.40K
- Marktkap.
- 72.34M
- Tief
- 0.961
- Umsatz
- 724.51K
- EV/EBITDA, TTM
- 0.00
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
KI-Analyse of Spero Therapeutics Inc (SPRO)
KaufenSpero Therapeutics Inc is a good buy right now at a current price of $1.04, especially considering the analyst price target of $6, which suggests a potential upside of over 480%. The company has a strong gross margin of 100% and a favorable forward P/E ratio of 0, indicating no earnings pressure from valuations. However, the main risk is the significant net loss of $9.6 million reported in Q2 2026, which highlights ongoing financial challenges.
Analystenbewertungen (4)
+292.16% Aufwärtspotenzial
Kaufen
3 Kaufen
1 Halten
0 Verkaufen
Aktuell: 1.02
Tief
4.00
Durchschnitt
4.00
Hoch
4.00
Cantor Fitzgerald
Übergewichten
$6
2026-10-28
Cantor Fitzgerald
2026-10-28
Kursziel
$6
Übergewichten
H.C. Wainwright
Kaufen
$6
2026-09-14
H.C. Wainwright
2026-09-14
Kursziel
$6
Kaufen
HC Wainwright & Co.
Starker Kauf
$5
2025-01-30
HC Wainwright & Co.
2025-01-30
Kursziel
$5
Starker Kauf
Evercore ISI Group
Halten
$5
2024-12-20
Evercore ISI Group
2024-12-20
Kursziel
$5
Halten
HC Wainwright & Co.
Starker Kauf
$5
2024-12-02
HC Wainwright & Co.
2024-12-02
Kursziel
$5
Starker Kauf
Bewertungskennzahlen
Das aktuelle erwartete KGV von Spero Therapeutics Inc (SPRO) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -1.67.
Whales, die SPRO halten
Event-Zeitleiste
News
9.508-19NASDAQ.COMSpero Therapeutics Reports Q2 2026 Earnings with Strategic Focus Shift
5.007-27NASDAQ.COMSpero Therapeutics Appoints New Chief Medical Officer to Enhance Clinical Leadership
7.507-15Yahoo FinanceInnovent Biologics Licenses IBI355 to Spero for Up to $1.1 Billion
7.507-14seekingalphaSpero Therapeutics Secures $105M Financing and $1.1B Licensing Deal
2.007-14seekingalphaSpero Secures $105M Non-Recourse Financing from KKR Affiliate
SPRO FAQ – beantwortet von Alphio AI
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Spero Therapeutics Inc is a good buy right now at a current price of $1.04, especially considering the analyst price target of $6, which suggests a potential upside of over 480%. The company has a strong gross margin of 100% and a favorable forward P/E ratio of 0, indicating no earnings pressure from valuations. However, the main risk is the significant net loss of $9.6 million reported in Q2 2026, which highlights ongoing financial challenges.
4 analysts cover SPRO: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 4.00.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenÄhnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.